{"grounding": "Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous, resisting distillation to a single, cohesive disorder. Instead, each affected individual develops a virtually unique form of Parkinson's syndrome. Clinical manifestations consist of variable motor and nonmotor features, and myriad overlaps are recognized with other neurodegenerative conditions. Although most commonly characterized by alpha-synuclein protein pathology throughout the central and peripheral nervous systems, the distribution varies and other pathologies commonly modify PD or trigger similar manifestations. Nearly all PD is genetically influenced. More than 100 genes or genetic loci have been identified, and most cases likely arise from interactions among many common and rare genetic variants. Despite its complex architecture, insights from experimental genetic dissection coalesce to reveal unifying biological themes, including synaptic, lysosomal, mitochondrial, andimmune-mediated mechanisms of pathogenesis. This emerging understanding of Parkinson's syndrome, coupled with advances in biomarkers and targeted therapies, presages successful precision medicine strategies.", "generated_text": "Parkinson's syndrome, encompassing idiopathic Parkinson's disease (PD) and atypical parkinsonism, is characterized by motor and non-motor symptoms, with significant genetic and clinical heterogeneity. Recent advances in functional genomics have highlighted the role of oligogenic inheritance, where multiple genetic variants contribute to disease susceptibility. Key genes, such as GBA and LRRK2, are associated with lysosomal and mitochondrial dysfunction, respectively, while alpha-synuclein plays a critical role in synaptic pathology. These genetic factors interact to disrupt cellular processes, leading to the progressive loss of dopaminergic neurons. Understanding the complex interplay between these genetic elements and their impact on cellular pathways, including protein aggregation and neuroinflammation, is crucial for developing targeted therapies. This review synthesizes current knowledge on the genetic architecture and pathogenic mechanisms of Parkinson's syndrome, emphasizing the importance of a multifaceted approach to unravel the disease's heterogeneity.", "label": 1}